MedPath

Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13

Phase 2
Completed
Conditions
Opioid-Related Disorders
Registration Number
NCT00000231
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Brief Summary

The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Retention
Overall treatment outcome
Naltrexone consumption
Drug use
Weeks abstinent
Weeks continuous abstinence
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Treatment Research Center

🇺🇸

Burlington, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath